Construction and validation of a survival prognostic model for stage III hepatocellular carcinoma: a real-world, multicenter clinical study

BMC Gastroenterology - Tập 23 Số 1
Shuai Hao1, Rui Luo2, Wei Li1, Ruhan Zhao1, Tingxiang Qi1, Zichen Wang1, Nan Li1, Ming Liu1
1Department of Oncology, The Third Hospital of Hebei Medical University, Shijiazhuang, Hebei, PR China
2Department of Hepatobiliary and Pancreatic Surgery, Third Xiangya Hospital, Central South University, Changsha, Hunan, PR China

Tóm tắt

Abstract Objective To construct a survival prediction model for patients with TNM stage III hepatocellular carcinoma (HCC) to guide the clinical diagnosis and treatment of HCC patients and improve prognosis. Methods Based on data from patients with stage III (AJCC 7th TNM stage) recorded by the American Institute of Cancer Research from 2010 to 2013, risk factors affecting the prognosis were screened by Cox univariate and multivariate regression, line plots was constructed, and the credibility of the model was verified by Boostrap method. ROC operating curves, calibration curves and DCA clinical decision curves were used to evaluate the model, and Kaplan–Meier was used for survival analysis was used to evaluate the efficacy of the model. External survival data from patients newly diagnosed with stage III hepatocellular carcinoma during 2014–2015 were used to validate and fit the model and to optimize the model. Results Age > 75 years vs.18-53 years [HR = 1.502; 95%CI(1.134–1.990)], stage IIIC vs. Stage IIIA [HR = 1.930; 95%CI(1.509–2.470)], lobotomy vs. non-surgery [HR = 0.295; 95%CI(0.228–0.383)], radiotherapy vs. non-radiotherapy [HR = 0.481; 95%CI(0.373–0.619)], chemotherapy vs. Non-chemotherapy [HR = 0.443; 95%CI(0.381–0.515)], positive serum AFP before treatment vs. negative [HR = 1.667; 95%CI(1.356–2.049)], the above indicators are independent prognostic factors for patients with stage III hepatocellular carcinoma, and the P values for the above results were less than 0.05. A joint prediction model was constructed based on age, TNM stage, whether and how to operate, whether to receive radiotherapy, whether to receive chemotherapy, pre-treatment serum AFP status and liver fibrosis score. The consistency index of the improved prognosis model was 0.725. Conclusions The traditional TNM staging has limitations for clinical diagnosis and treatment, while the Nomogram model modified by TNM staging has good predictive efficacy and clinical significance.

Từ khóa


Tài liệu tham khảo

Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.

Feng J, He Y, Wan J, et al. Pulmonary metastases in newly diagnosed hepatocellular carcinoma: a population-based retrospective study. HPB (Oxford). 2020;22(9):1295–304.

Jun L, Zhenlin Y, Renyan G, et al. Independent factors and predictive score for extrahepatic metastasis of hepatocellular carcinoma following curative hepatectomy. Oncologist. 2012;17(7):963–9.

Kanda M, Tateishi R, Yoshida H, et al. Extrahepatic metastasis of hepatocellular carcinoma: incidence and risk factors. Liver Int. 2008;28(9):1256–63.

Yang Y, Nagano H, Ota H, et al. Patterns and clinicopathologic features of extrahepatic recurrence of hepatocellular carcinoma after curative resection. Surgery. 2007;141(2):196–202.

Hong SS, Kim TK, Sung KB, et al. Extrahepatic spread of hepatocellular carcinoma: a pictorial review. Eur Radiol. 2003;13(4):874–82.

Chen X, Lu Y, Shi X, et al. Epidemiological and clinical characteristics of five rare pathological subtypes of hepatocellular carcinoma. Front Oncol. 2022;8(12):864106.

Chen H, Zhuang H. Current status of chronic hepatitis B epidemiology in China. Hepatol. 2018;01:8–9.

Wang Y. Study on the prognostic value of radiotherapy in giant hepatocellular carcinoma and construction of a graph model. China: Fujian Medical University; 2021.

Zongyi G, Chenglong M, Hong Z, et al. Application of optimal radiotherapy based on subhepatic segment functional unit protection in precision radiotherapy for liver cancer. Chin J Med Sci. 2002;12(04):165–8.

Sacco R, Ramai D, Tortora R, et al. Role of etiology in hepatocellular carcinoma patients treated with Lenvatinib: a counterfactual event-based mediation analysis. Cancers (Basel). 2023;15(2):381.

Chidambaranathan-Reghupaty S, Fisher PB, Sarkar D. Hepatocellular carcinoma (HCC): epidemiology, etiology and molecular classification. Adv Cancer Res. 2021;149:1–61.

A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hep. 1998;28(3):751-5.

Agarwal R, Narayan J, Bhattacharyya A, Saraswat M, Tomar AK. Gene expression profiling, pathway analysis and subtype classification reveal molecular heterogeneity in hepatocellular carcinoma and suggest subtype specific therapeutic targets. Cancer Genet. 2017;216-217:37-51.

Zhang H, Du X, Dong H, et al. Risk factors and predictive nomograms for early death of patients with advanced hepatocellular carcinoma: a large retrospective study based on the SEER database. BMC Gastroenterol. 2022;22(1):348.

Wang Dongmei, Gao Shile, Lu Donghui, et al. Analysis of the effect of radiotherapy on primary hepatocellular carcinoma and the related factors of radioactive liver injury. J Anhui Med. 2022;26(02):243-246

Li Guangxiao, Xiao Peng, ZHEN Yulan, et al. Influence factors of intensity modulated radiotherapy combined with hepatic artery chemoembolization in the treatment of hepatocellular carcinoma complicated with portal vein cancer thrombus. Chin Med Guide. 2021;19(23):1–3.

Ya RH, Guy DE. Transcatheter arterial chemoembolization plus radiotherapy compared with chemoembolization alone for hepatocellular carcinoma: a systematic review and metaanalysis. JAMA Oncol. 2015;1(6):756–65.

Liu M, Xu M, Tang T. Association between chemotherapy and prognostic factors of survival in hepatocellular carcinoma: a SEER population-based cohort study. Sci Rep. 2021;11(1):23754.

Ryoko Y. Impact of alpha-fetoprotein on hepatocellular carcinoma development during entecavir treatment of chronic hepatitis B virus infection. J Gastroenterol. 2015;50:785–94.

Jordi B, et al. Prognostic factors and predictors of sorafenib beneft in patients with hepatocellular carcinoma: Analysis of two phase III studies. J Hepatol. 2017;67:999–1008.

Luo P, Wu S, Yu Y, et al. Current Status and Perspective Biomarkers in AFP Negative HCC: Towards Screening for and Diagnosing Hepatocellular Carcinoma at an Earlier Stage. Pathol Oncol Res. 2020;26(2):599–603.

Chen T, Dai X, Dai J, et al. AFP promotes HCC progression by suppressing the HuR-mediated Fas/FADD apoptotic pathway. Cell Death Dis. 2020;11(10):822.

Notarpaolo A, Layese R, Magistri P, et al. Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC. J Hepatol. 2017;66(3):552–9.

Lin E, Zou B, Zeng G, et al. The impact of liver fibrosis on microvascular invasion and prognosis of hepatocellular carcinoma with a solitary nodule: a Surveillance, Epidemiology, and End Results (SEER) database analysis. Ann Transl Med. 2021;9(16):1310.

Stefanini B, Ielasi L, Chen R, et al. TKIs in combination with immunotherapy for hepatocellular carcinoma. Expert Rev Anticancer Ther. 2023;23(3):279–91.

D’Avola D, Granito A, Torre-Aláez M, et al. The importance of liver functional reserve in the non-surgical treatment of hepatocellular carcinoma. J Hepatol. 2022;76(5):1185–98.

Yao J, Liang X, Liu Y, et al. Trends in Incidence and Prognostic Factors of Two Subtypes of Primary Liver Cancers: A Surveillance, Epidemiology, and End Results-Based Population Study. Cancer Control. 2022;29:10732748211051548.

Perz JF, Armstrong GL, Farrington LA, et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006;45(4):529–38.

Smith SM, Stinson FS, Dawson DA, et al. Race/ethnic differences in the prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the national epidemiologic survey on alcohol and related conditions. Psychol Med. 2006;36(7):987–98.

Satriano L, Lewinska M, Rodrigues PM, et al. Metabolic rearrangements in primary liver cancers: Cause and consequences. Nat Rev Gastroenterol Hepatol. 2019;16(12):748–66.

Zhang JF, Shu ZJ, Xie CY, et al. Prognosis of unresectable hepatocellular carcinoma: comparison of seven staging systems (TNM, Okuda, BCLC, CLIP, CUPI, JIS, CIS) in a Chinese cohort. PLoS One. 2014;9(3):e88182.